• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

13.57 +0.63 (+4.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vor Biopharma Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 23, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
February 23, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
December 23, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces $150 Million Private Placement
December 15, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
November 10, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
November 10, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
November 08, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in Upcoming Investor Conferences
November 07, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
November 03, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
October 29, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
October 22, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
October 17, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
October 16, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
October 14, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
September 29, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
September 23, 2025
Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launches 
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
September 17, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
September 12, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
September 02, 2025
Experienced legal leader brings deep expertise in governance, strategic transactions, and risk management to support Vor Bio’s growth 
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy
August 27, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in Upcoming Investor Conferences
August 26, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
August 13, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
August 04, 2025
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities 
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
July 21, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2025
From Vor Biopharma
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap